VIRGINIA RETIREMENT SYSTEMS ET Al Sells 507,868 Shares of Gilead Sciences, Inc. $GILD

VIRGINIA RETIREMENT SYSTEMS ET Al reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 524,427 shares of the biopharmaceutical company’s stock after selling 507,868 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Gilead Sciences were worth $78,166,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. BlackRock Inc. bought a new position in shares of Gilead Sciences in the second quarter worth about $15,393,785,000. Legal & General Group Plc acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $1,316,606,000. Deutsche Bank AG purchased a new position in shares of Gilead Sciences in the second quarter worth about $918,387,000. Jupiter Topco LLC acquired a new stake in shares of Gilead Sciences in the second quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences during the second quarter worth $398,905,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 3.1%

NASDAQ GILD opened at $170.68 on Friday. The stock has a fifty day simple moving average of $150.87 and a 200-day simple moving average of $139.79. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a twelve month low of $114.02 and a twelve month high of $175.65.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.47 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s payout ratio is currently -122.85%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the insider directly owned 113,684 shares of the company’s stock, valued at $17,759,714.48. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock valued at $15,877,860 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GILD has been the subject of a number of analyst reports. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday. Scotiabank lifted their price target on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research note on Friday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $184.00 price target on shares of Gilead Sciences in a report on Friday. Jefferies Financial Group reissued a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a report on Friday, October 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.